{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:59:31Z","timestamp":1775091571732,"version":"3.50.1"},"reference-count":30,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005681","name":"Genesis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005681","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Apremilast is an oral phosphodiesterase\u20104 inhibitor indicated for patients with moderate\u2010to\u2010severe chronic plaque psoriasis and active psoriatic arthritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To examine the effectiveness of apremilast on Dermatology Life Quality Index (DLQI), Psoriasis Area and Severity Index (PASI) and nail, scalp and palmoplantar involvement, when administered prior to biologics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This 52\u2010week real\u2010world study included biologic\u2010naive adults with moderate psoriasis (psoriasis\u2010involved body surface area 10% to &lt;20%, or PASI 10 to &lt;20 and DLQI 10 to &lt;20). Apremilast was initiated \u22647\u00a0days before enrolment. Data from the first 100 eligible patients who completed 24\u00a0weeks (W24) of observation (or were prematurely withdrawn) are presented in this interim analysis using the last\u2010observation\u2010carried\u2010forward imputation method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eligible patients (mean age: 49.9\u00a0years; 71.0% males; median disease duration: 8.0\u00a0years) were consecutively enrolled between April and October 2017, by 18 dermatology specialists practising in hospital outpatient settings in Greece. Baseline DLQI (median: 12.0) and PASI (median: 11.7) scores improved (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) at all postbaseline timepoints (Weeks 6, 16 and 24; W24 median decreases: 9.0 and 9.4 points respectively). At W24, DLQI \u22645, DLQI 0 or 1, and PASI\u201075 response rates were 63.0%, 25.0% and 48.0% respectively. The Nail Psoriasis Severity Index score in patients with baseline nail involvement (<jats:italic>n<\/jats:italic>\u00a0=\u00a057) decreased at all postbaseline timepoints (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001; W24 median decrease: 20.0 points). At W24, 50.0% and 51.7% of patients with baseline scalp (<jats:italic>n<\/jats:italic>\u00a0=\u00a076) and palmoplantar (<jats:italic>n<\/jats:italic>\u00a0=\u00a029) involvement respectively achieved postbaseline Physician\u2019s Global Assessment (PGA) score of 0 or 1 if baseline score was \u22653, or 0 if baseline score was 1 or 2. The adverse drug reaction rate was 21.0% (serious: 2.0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These interim results indicate that through 24\u00a0weeks, apremilast improved quality of life and reduced disease severity in biologic\u2010naive patients with moderate plaque psoriasis, while demonstrating safety consistent with the known safety profile.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.17392","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:21:41Z","timestamp":1621988501000},"page":"1838-1848","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and safety of apremilast in biologic\u2010na\u00efve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study"],"prefix":"10.1111","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8997-9889","authenticated-orcid":false,"given":"D.","family":"Ioannides","sequence":"first","affiliation":[{"name":"1<sup>st<\/sup> University Department of Dermatology Aristotle University of Thessaloniki Hospital of Venereal &amp; Skin Diseases of Thessaloniki Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Antonakopoulos","sequence":"additional","affiliation":[{"name":"Genesis Pharma Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Georgiou","sequence":"additional","affiliation":[{"name":"Department of Dermatology University General Hospital of Patras Patras Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Chasapi","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology Department of N.H.S \u2018Andreas Sygros\u2019 Hospital Athens Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Katsantonis","sequence":"additional","affiliation":[{"name":"Dermatology Unit Piraeus Regional General Hospital \u2018Tzaneio\u2019 Piraeus Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Drosos","sequence":"additional","affiliation":[{"name":"Department of Dermatology General Hospital of Xanthi Xanthi Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4841-7484","authenticated-orcid":false,"given":"D.","family":"Rigopoulos","sequence":"additional","affiliation":[{"name":"1<sup>st<\/sup> Department of Dermatology &amp; Venereology National Kapodistrian University of Athens \u2018Andreas Sygros\u2019 Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Antoniou","sequence":"additional","affiliation":[{"name":"1<sup>st<\/sup> Department of Dermatology &amp; Venereology National Kapodistrian University of Athens \u2018Andreas Sygros\u2019 Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Anastasiadis","sequence":"additional","affiliation":[{"name":"Department of Dermatology General Hospital of Athens \u2018Evangelismos\u2019 Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0252-8314","authenticated-orcid":false,"given":"I.","family":"Bassukas","sequence":"additional","affiliation":[{"name":"Department of Skin and Venereal Diseases University of Ioannina Ioannina Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ioannidou","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology General Hospital of Heraklion \u2018Venizeleio\u2010 Pananeio\u2019 Heraklion Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Protopapa","sequence":"additional","affiliation":[{"name":"Outpatient Department of Dermatology General Hospital of Sitia Sitia Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Neofotistou","sequence":"additional","affiliation":[{"name":"Dermatology Department Konstantopoulio District General Hospital of Nea Ionia Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Krasagakis","sequence":"additional","affiliation":[{"name":"Department of Dermatology University General Hospital of Heraklion Heraklion Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Aronis","sequence":"additional","affiliation":[{"name":"Clinical Dermatology Hellenic Airforce 251 General Hospital Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Papageorgiou","sequence":"additional","affiliation":[{"name":"State Department of Dermatology Hospital of Venereal &amp; Skin Diseases of Thessaloniki Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Lazaridou","sequence":"additional","affiliation":[{"name":"2<sup>nd<\/sup> University Department of Dermatology Aristotle University of Thessaloniki General Hospital of Thessaloniki \u2018Papageorgiou\u2019 Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Patsatsi","sequence":"additional","affiliation":[{"name":"2<sup>nd<\/sup> University Department of Dermatology Aristotle University of Thessaloniki General Hospital of Thessaloniki \u2018Papageorgiou\u2019 Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Lefaki","sequence":"additional","affiliation":[{"name":"Dermatology Unit 'EUROMEDICA\u2019 General Clinic Thessaloniki Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.V.","family":"Roussaki\u2010Schulze","sequence":"additional","affiliation":[{"name":"University Clinic of Dermatology University General Hospital of Larissa Larissa Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Satra","sequence":"additional","affiliation":[{"name":"Genesis Pharma Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-6827","authenticated-orcid":false,"given":"Z.","family":"Anagnostopoulos","sequence":"additional","affiliation":[{"name":"Genesis Pharma Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Papakonstantis","sequence":"additional","affiliation":[{"name":"Clinic of Dermatology 401 General Military Hospital of Athens Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052935"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630500482886"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"key":"e_1_2_6_5_1","first-page":"801","article-title":"Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study","volume":"16","author":"Strober B","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_2_6_8_1","volume-title":"Otezla [summary of product characteristics]","author":"European Medicines Agency"},{"key":"e_1_2_6_9_1","volume-title":"Committee for the Monitoring of Pharmaceutical Expenditure, the Completion of Diagnostic\/Therapeutic Protocols and the Establishment of Patient Registries. Psoriasis Diagnostic and Therapeutic Protocols","author":"Hellenic Ministry of Health","year":"2018"},{"key":"e_1_2_6_10_1","volume-title":"Guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Psoriasis","author":"European Medicines Agency","year":"2004"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8510(90)90421-9"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890109002087"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-009-0928-8"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1265"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1256-y"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.1083"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_2_6_20_1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1610-0387.2010.07412.x","article-title":"Scalp psoriasis","volume":"9","author":"Wozel G","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_6_21_1","unstructured":"ReichK BomasS KorgeBet\u00a0al.Physician\u2010 and patient\u2010reported outcomes with apremilast for patients with plaque psoriasis during routine clinical care in Germany: a second interim analysis [poster 7104]. Presented at: Annual Meeting of the American Academy of Dermatology; February 16\u201020 2018;San Diego CA."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14832"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16431"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13764"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.12.018"},{"key":"e_1_2_6_26_1","first-page":"1240","article-title":"Real\u2010world clinical experience with apremilast in a large US retrospective cohort study of patients with moderate to severe plaque psoriasis","volume":"16","author":"Armstrong A","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.072"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","unstructured":"IoannidesD TampouratziE PlatsidakiEet\u00a0al.Scalp palmoplantar and nail involvement in moderate bio\u2010na\u00efve psoriasis patients treated with apremilast: 6\u2010week interim results of a real\u2010world multicenter prospective study in Greece [poster 165]. Presented at: Annual Meeting of the European Society for Dermatological Research; September 18\u201021 2019;Bordeaux France.","DOI":"10.1016\/j.jid.2019.07.169"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543400903105406"},{"key":"e_1_2_6_30_1","first-page":"734","article-title":"Methods for imputing missing efficacy data in clinical trials of biologic psoriasis therapies: implications for interpretations of trial results","volume":"16","author":"Langley RGB","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12583"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T01:00:26Z","timestamp":1692320426000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/jdv.17392"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17392","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"2021-02-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}